

EZASSI SIGNALS

GLP-1 Companion Products in Foods and Supplements

Commercial Signals · September 2026

A Commercial watch on demand from people taking GLP-1 medicines, read from the contract manufacturer’s side. It asks whether that demand is turning into real, formulation-specific orders, which formats and nutrition specifications brands and retailers are settling on, and where the regulatory limits on claims sit. Six signals from one cycle.

#	SIGNAL	CONFIDENCE	HORIZON	STATUS
1	Four independent panel datasets converge on the same basket shift: GLP-1 households are moving structurally toward protein, fiber, and functional nutrition	High	Immediate (0–3 months)	Review
2	Retailers are institutionalizing the protein-fiber shift through private-label platforms — signaling durable, repeat-order intent rather than one-off branded launches	Medium	Short-term (3–12 months)	Review
3	Product format specifications are beginning to crystallize — bars at 15g protein and 10g fiber, protein coffee at 10g per scoop, and portion-controlled frozen meals with dietitian-developed specs — giving manufacturers an early formulation template	Medium	Immediate (0–3 months)	Verified
4	An oral GLP-1 product reached the U.S. market in 2026 at a sub-200-dollar direct-pay price, and a second oral option launched internationally — together materially expanding the addressable population beyond injection-tolerant users	Medium	Short-term (3–12 months)	Review
5	GLP-1 enforcement activity is targeting drug-like and peptide claims, not conventional protein-fiber positioning — defining where the regulatory risk boundary sits for food and supplement brands	Medium	Short-term (3–12 months)	Review
6	ADM is the only named food-ingredient supplier publicly positioning GLP-1 formulation capability — the near-total silence from food-focused co-manufacturers indicates dedicated manufacturing investment has not yet begun	Medium	Short-term (3–12 months)	Review

Every signal rests on two or more dated events. Confidence is published as a band. Where a signal sits below High, the reasoning names the evidence that is missing. Status says where the evidence stands: Verified, Review, or Inconclusive — we looked, and the evidence does not yet support a firmer call.

SIGNAL 1 OF 6

Four independent panel datasets converge on the same basket shift: GLP-1 households are moving structurally toward protein, fiber, and functional nutrition

HIGH Immediate (0–3 months) · Commercial & Market Signals · Review

Numerator, NIQ, BCG, PwC, and Morning Consult data — drawn from separate methodologies and survey windows — all independently point to the same directional shift in GLP-1 household purchasing, giving a contract manufacturer high confidence in the product types that will be ordered.

REASONING

A signal requires two or more related events pointing in the same direction. Here, five independent research organizations — Numerator, IGD/NIQ, BCG, PwC, and Morning Consult — all published findings in a narrow window (June–September 2026) showing the same directional basket change. No single study is definitive, but the convergence across distinct methodologies (panel transaction data, survey stated intent, and declared purchasing behavior) substantially reduces the probability that any one finding is a methodological artifact. The pattern is therefore elevated to a high-confidence signal, though it remains a demand signal rather than proof of placed manufacturing orders.

PATTERN

Numerator found GLP-1 users' grocery spending was nearly 4% lower than comparable households, with basket composition shifting away from pantry staples toward fresh protein, seafood, functional nutrition, and intentional snacks. A separate Supermarket News/Numerator report dated August 5, 2026 placed 22% of U.S. households with a current GLP-1 user and confirmed 3.8% lower grocery spend. IGD and NIQ (July 23, 2026) reported 42% of GLP-1 users eating more protein and 34% more fiber. BCG (August 3, 2026) reported active users planned 11% more monthly spending on high-protein foods. PwC (June 22, 2026) reported 35% of current users buying more packaged protein. Morning Consult (survey conducted June 25–27, 2026, among 241 current GLP-1 users) found 52% buying more high-protein dairy, 48% more single-serve or portion-controlled foods, and 43% more protein drinks.

IMPLICATION

For a contract manufacturer, this convergence removes the 'is there real demand?' uncertainty. The product brief implied by the data is not speculative: high-protein, fiber-containing, portion-controlled, nutrient-dense products in formats suitable for smaller eating occasions. The risk is not demand direction but demand magnitude and whether brands will convert this into repeat orders rather than one-time launches.

RECOMMENDED ACTION

Use the Morning Consult attribute rankings — satiety (84%), high protein (81%), lower sugar (79%), digestive ease (79%), fiber (75%) — as a formulation brief hierarchy when quoting GLP-1-adjacent customers; present this multi-source convergence as the demand rationale in sales collateral.

SOURCES & WHAT THEY SIGNAL

- [IGD and NIQ: GLP-1 users eating more protein and fiber](#) — Independent research organization data: 42% of GLP-1 users eating more protein, 34% more fiber — corroborating the Numerator basket shift.

- **PwC: GLP-1 consumer trends — packaged protein purchasing** — 35% of current users buying more packaged protein, while 61% buying fewer sweet treats.
- **BCG: GLP-1 consumer behavior shift — intended spending on protein and fiber** — Active users report 11% higher intended monthly spending on high-protein foods, supporting the direction of observed purchasing data.
- **Morning Consult survey: GLP-1 users reshape frozen and refrigerated food demand (Prepared Foods)** — Survey of 241 current GLP-1 users quantifying the attribute priority stack (satiety, protein, lower sugar, digestive ease, fiber) and specific format preferences including high-protein dairy, single-serve foods, and protein drinks.
- **Numerator: GLP-1 users shift grocery baskets toward protein, fiber, and functional nutrition (Food Dive)** — Panel transaction data showing nearly 4% lower grocery spending among GLP-1 households and a compositional shift toward protein, seafood, functional nutrition, and intentional snacks.
- **Numerator: 22% of U.S. households now have a GLP-1 user (Supermarket News)** — Scale and spending differential of GLP-1 households; 3.8% lower grocery spend and continued shift toward fresh protein, seafood, and functional nutrition.

SIGNAL 2 OF 6

Retailers are institutionalizing the protein-fiber shift through private-label platforms — signaling durable, repeat-order intent rather than one-off branded launches

MEDIUM Short-term (3–12 months) · Commercial & Market Signals · Review

Multiple grocery chains are embedding protein and fiber into their own-brand portfolios through structured range expansions, which represents a more durable manufacturing-order signal than branded GLP-1 badge launches.

REASONING

Private-label expansion is a stronger durability indicator than branded launches because retailers commit internal buying, shelf space, and category management resources to own-brand products. Finding three named grocery chains (Meijer, Kroger, Hy-Vee) each executing distinct but directionally identical protein and fiber private-label programs within the same period meets the two-or-more-events threshold for a signal. The evidence does not rest on GLP-1-specific labeling — it rests on product specifications (fiber thresholds, high-protein positioning) that would require real manufacturing commitments. Confidence is not higher because available sources do not disclose individual product protein or fiber quantities for Kroger or Hy-Vee Dietitian Dishes, and the exact product counts cited in earlier drafts carry a verification flag.

PATTERN

Meijer had more than 120 store-brand products with at least 5 grams of fiber per serving and planned additional protein-heavy private-label products including sesame protein pasta salad under Frederik's by Meijer and double-smoked beef sticks under True Goodness. Kroger extended its Simple Truth private-label brand with a protein-focused line that reportedly exceeded 80 high-protein meals and snacks. Hy-Vee launched its Dietitian Dishes line in February 2026 with more than 15 frozen entrées developed by registered dietitians targeting heart disease, diabetes, and GLP-1-aligned eating. Costco's Kirkland Signature Ultra Filtered Protein Milk and Kirkland Signature Beef Sticks were described as doing 'tremendous volume' and 'taken off,' respectively. Hy-Vee also added BTR Nation protein bars and Javvy protein coffee to its assortment, reportedly within approximately two months of the September 22, 2026 report date.

IMPLICATION

Private-label protein and fiber commitments at the scale described — spanning multiple major chains, multiple formats (frozen meals, dairy beverages, meat snacks, bars, prepared salads), and minimum fiber thresholds — are more likely to generate repeat contract-manufacturing volume than branded badge products. A co-manufacturer capable of hitting 5g+ fiber and high-protein specifications across multiple formats (frozen, shelf-stable, refrigerated) is better positioned than one optimized for a single format.

RECOMMENDED ACTION

Prioritize outreach to retailers' private-label development and procurement teams at Meijer, Kroger, and regional grocery chains; lead with demonstrated capability across at least two format types (e.g., frozen entrée plus shelf-stable bar or snack) and the ability to certify protein and fiber per-serving claims.

SOURCES & WHAT THEY SIGNAL

- [Hy-Vee and Iowa grocers adapting to GLP-1 eating patterns \(Des Moines Register\)](#) — Hy-Vee's recent addition of BTR Nation and Javvy; Nestlé Vital Pursuit on shelf at Hy-Vee and Fareway, establishing retailer-level assortment commitment to GLP-1-adjacent products.
- [Kroger Simple Truth Protein and Hershey, Pepsi competitive dynamics \(TheStreet\)](#) — Kroger's Simple Truth Protein private-label extension described as exceeding 80 high-protein meals and snacks — evidence of retailer-scale protein range commitment.
- [Hy-Vee Dietitian Dishes and private-label health innovation \(IGD\)](#) — Hy-Vee's February 2026 Dietitian Dishes launch with 15+ frozen entrées targeting GLP-1-aligned eating; IGD's identification of probiotics, gut health, fiber, collagen, and creatine as future private-label innovation areas.
- [Meijer private-label fiber and protein expansion \(Grocery Dive\)](#) — Meijer's 120+ store-brand products meeting a 5g fiber threshold and additional protein-heavy items under named sub-brands; Kirkland Signature products doing high volume.

SIGNAL 3 OF 6

Product format specifications are beginning to crystallize — bars at 15g protein and 10g fiber, protein coffee at 10g per scoop, and portion-controlled frozen meals with dietitian-developed specs — giving manufacturers an early formulation template

MEDIUM Immediate (0–3 months) · Commercial & Market Signals · Verified

Specific, verifiable serving-level specifications are now appearing in retail assortments, providing the first concrete input parameters a contract manufacturer would need to price and equip against.

REASONING

Most GLP-1-adjacent product coverage lacks serving-level detail, making it uninformative for a co-manufacturer. The BTR Nation and Javvy examples are exceptions: the Des Moines Register report names specific grams of protein and fiber per serving alongside the format (palm-sized bar, coffee powder). The Meijer 5g fiber minimum and the Morning Consult attribute priority stack add further specification context. Together these events begin to define a real formulation brief — not just a trend direction. Confidence is not higher because only two products have clearly cited serving-level specifications, and the frozen-meal segment lacks published macros in the available findings.

PATTERN

BTR Nation bars described as palm-sized, providing 15 grams of protein and 10 grams of fiber per bar, were added to Hy-Vee approximately two months before the September 22, 2026 report date. Javvy protein coffee was reported at 10 grams of protein per scoop in the same report. Nestlé Vital Pursuit frozen meals carry explicit 'GLP-1 Friendly' labeling and have been on shelf since 2024 at Hy-Vee and Fareway. Hy-Vee's Dietitian Dishes launched February 2026 with more than 15 frozen entrées developed by registered dietitians targeting GLP-1-aligned eating. Meijer's private-label fiber threshold of at least 5 grams per serving is used across more than 120 store-brand products. Morning Consult survey data establish that digestive ease (79%) and fiber (75%) are near-mandatory attributes for GLP-1 users alongside protein (81%) and lower sugar (79%). SlimFast announced a repositioning centered on creatine, collagen, protein, and fiber as its new product development focus.

IMPLICATION

For a contract manufacturer, the BTR Nation and Javvy specifications (15g protein and 10g fiber in a shelf-stable bar; 10g protein in a powder) are actionable recipe anchors. The 5g fiber floor Meijer has set for its store brand is a minimum viable threshold for private-label bids. Frozen-meal specs remain underspecified in the available evidence, but the Dietitian Dishes positioning suggests dietitian-reviewed macros will be a qualification criterion. Creatine and collagen are named as future R&D priorities by SlimFast and as innovation areas by IGD — these ingredients require sourcing and blending capability that not all co-manufacturers hold.

RECOMMENDED ACTION

Build a proof-of-concept product matrix spanning at least three formats — shelf-stable bar, protein powder sachet, and frozen entrée — each hitting 15g protein and 5g fiber minimum, and document cost-per-serving at those specs to use in customer conversations.

SOURCES & WHAT THEY SIGNAL

- [Hy-Vee and Iowa grocers adapting to GLP-1 eating patterns \(Des Moines Register\)](#) — BTR Nation bar at 15g protein and 10g fiber, Javvy protein coffee at 10g protein per scoop, and Nestlé Vital Pursuit 'GLP-1 Friendly' frozen meals — the only cited serving-level specifications in the available findings.
- [Morning Consult survey: GLP-1 users reshape frozen and refrigerated food demand \(Prepared Foods\)](#) — Consumer-side attribute priority ranking (satiety, protein, lower sugar, digestive ease, fiber, gut health) that translates directly into formulation objectives.
- [SlimFast GLP-1 repositioning toward creatine, collagen, protein, and fiber \(NutraIngredients\)](#) — A named brand publicly specifying creatine, collagen, protein, and fiber as its GLP-1-era product development pillars — the first brand-side ingredient convergence signal.
- [Hy-Vee Dietitian Dishes and private-label health innovation \(IGD\)](#) — Hy-Vee Dietitian Dishes: 15+ frozen entrées, dietitian-developed, GLP-1-aligned — and IGD's forward-looking identification of probiotics, gut health, fiber, collagen, and creatine as next innovation categories.
- [Meijer private-label fiber and protein expansion \(Grocery Dive\)](#) — Meijer's 5g fiber per serving as a minimum threshold for private-label positioning — a concrete retailer-set specification.

SIGNAL 4 OF 6

An oral GLP-1 product reached the U.S. market in 2026 at a sub-200-dollar direct-pay price, and a second oral option launched internationally — together materially expanding the addressable population beyond injection-tolerant users

MEDIUM Short-term (3-12 months) · Regulatory & Policy Signals · Review

Foundayo's April 2026 approval with a 149-dollar direct-pay monthly entry point removes two of the largest barriers to GLP-1 adoption, suggesting the user base — and companion food demand — will grow from its already elevated level. A second oral GLP-1 option has also been reported in international markets, though the specific launch details are still to be confirmed.

REASONING

Oral availability removes needle aversion, the most commonly cited barrier after cost. Foundayo's direct-pay price of 149 dollars per month at the starting dose, alongside a 25-dollar commercial insurance co-pay pathway and a 50-dollar Medicare Part D pathway from July 2026, materially lowers the financial bar relative to historical injectable list prices. A second oral GLP-1 option from Novo Nordisk has also been reported, adding further validation of the oral format commercially, though its specific launch dates and markets could not yet be confirmed. Foundayo's approval and pricing are verified, source-cited events from an FDA press release and Eli Lilly investor communications, not forecast. Confidence is not higher because uptake, persistence, and the food-purchasing translation of new oral users are not yet documented in the available findings.

PATTERN

FDA approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 receptor agonist, for adults with obesity or overweight plus at least one comorbid condition. Eli Lilly stated that Foundayo is available through LillyDirect at a self-pay price starting at 149 dollars per month for the lowest dose, with eligible commercial-insurance patients potentially paying as little as 25 dollars per month and eligible Medicare Part D beneficiaries potentially paying 50 dollars per month beginning July 1, 2026. Novo Nordisk has also reported an oral Wegovy product entering markets in 2026; the specific launch date and the markets covered could not yet be confirmed. Numerator data from August 5, 2026 already placed a GLP-1 user in 22% of U.S. households.

IMPLICATION

If oral adoption follows the pattern of injectable uptake but reaches populations previously deterred by injection or cost, the 22%-of-households baseline will grow. Each incremental household added to the GLP-1 user base is a potential buyer of protein-forward, fiber-containing, portion-controlled foods. For a contract manufacturer, this means the market for GLP-1-adjacent products is more likely to expand than to contract over the next 12 months, supporting investment in capacity rather than caution.

RECOMMENDED ACTION

Model two scenarios — one where oral adoption adds 3-5 percentage points to GLP-1 household penetration within 12 months and one where it simply substitutes for injectable — to stress-test any capacity investment

against both demand trajectories. Confirm the specific launch date, markets and commercial status of the oral Wegovy product before using those details.

SOURCES & WHAT THEY SIGNAL

- [Numerator: 22% of U.S. households now have a GLP-1 user \(Supermarket News\)](#) — Baseline household penetration against which the oral expansion will be measured.
- [Novo Nordisk Wegovy pill — news and IR materials](#) — Reported source for an oral Wegovy launch; specific date and markets are still to be confirmed before use in investment analysis.
- [Eli Lilly Foundayo approval and pricing — investor release](#) — Lilly-stated direct-pay price of 149 dollars per month starting dose, 25-dollar commercial co-pay pathway, and 50-dollar Medicare Part D pathway — the access and cost parameters that determine how many new users may enter.
- [FDA approves Foundayo \(orforglipron\) — press announcement](#) — Verified FDA approval of Foundayo as an oral GLP-1 receptor agonist, establishing regulatory clearance as a fact.

SIGNAL 5 OF 6

GLP-1 enforcement activity is targeting drug-like and peptide claims, not conventional protein-fiber positioning — defining where the regulatory risk boundary sits for food and supplement brands

MEDIUM Short-term (3-12 months) · Regulatory & Policy Signals · Review

Verified enforcement actions in August–September 2026 focused exclusively on semaglutide/tirzepatide-named products, compounding pharmacies, and 'GLP-1 biomimetic' supplements — not on high-protein or high-fiber foods using general GLP-1-user positioning, suggesting mainstream protein and fiber claims carry lower near-term enforcement risk.

REASONING

Enforcement pattern analysis is a legitimate signal when multiple independent actions share a consistent target profile. Three verified actions — FDA warning letter to Peptide Partners LLC, NAD-confirmed claim withdrawal by Willow Health Services, and FDA action against Empower Pharmacy — all targeted products making drug-equivalence or peptide-specific claims. None targeted a conventional food or supplement product using general 'GLP-1 friendly' or 'supports GLP-1 users' language. This is not an absence signal; it is a positive pattern across three sourced events that collectively define where regulators have chosen to draw enforcement lines. Confidence is held at Medium because the regulatory landscape can shift quickly. An industry summary also noted a separate FDA safety objection related to a 'GLP-1 biomimetic supplement' NDI notification, though the underlying detail of that objection could not be independently confirmed and is marked Inconclusive.

PATTERN

FDA issued a warning letter to Peptide Partners LLC (August 24, 2026) for products marketed as 'GLP-1 S (Semaglutide),' 'GLP-2 T (Tirzepatide),' and 'GLP-3 Reta (Retatrutide),' characterizing them as unapproved new drugs. NAD confirmed in July 2026 that Willow Health Services permanently discontinued claims of comparability to FDA-approved semaglutide and effectiveness without diet or exercise — claim types that crossed into drug-territory representations. FDA took action against Empower Pharmacy (September 18, 2026) for compounded weight-loss drug products alleged to too closely resemble FDA-approved versions. No finding in the available results documents an FTC action, FDA warning letter, or NAD ruling against a conventional food or supplement using high-protein, high-fiber, or general GLP-1-user-support language.

IMPLICATION

For a contract manufacturer advising customers on claim strategy, the evidence supports a working hypothesis that labeling products as 'high protein,' 'high fiber,' 'supports GLP-1 users,' or 'GLP-1 friendly' carries lower near-term enforcement exposure than naming specific peptides, claiming equivalence to prescription drugs, or using 'biomimetic' language. This is a judgment based on current enforcement pattern, not a legal opinion — and it does not mean general claims are immune. Brands and their compliance teams should be aware that the boundary could shift.

RECOMMENDED ACTION

Develop a claim-tier framework for GLP-1-adjacent customers: tier 1 (nutritional fact claims — protein grams, fiber grams) lowest risk; tier 2 (general user positioning — 'designed for GLP-1 users') moderate; tier 3 (mechanism or efficacy claims — 'supports GLP-1 pathways,' 'biomimetic') high risk — and ensure manufacturing agreements specify which tier the customer's label uses.

SOURCES & WHAT THEY SIGNAL

- [FDA action against Empower Pharmacy for compounded GLP-1 drugs \(CBS News\)](#) — September 2026 FDA action targeting compounded products resembling approved prescription drugs — further evidence enforcement is concentrated on the drug-side of the GLP-1 market.
- [NAD claim withdrawal by Willow Health Services \(Becker's Hospital Review\)](#) — NAD-confirmed permanent withdrawal of drug-comparability and no-diet-needed efficacy claims by a GLP-1-adjacent marketer — illustrating where the self-regulatory boundary sits.
- [FDA warning letter to Peptide Partners LLC — August 24, 2026](#) — Verified enforcement action against products using GLP-1/semaglutide, GLP-2/tirzepatide, and GLP-3/retatrutide naming — establishing drug-name claims as the primary FDA enforcement target.
- [Warning Letter Wednesday industry summary — September 23, 2026](#) — Industry summary referencing FDA activity related to a 'GLP-1 biomimetic supplement' NDI notification — potentially extending the enforcement perimeter toward supplement products making mechanism-level claims, but the specific objection details require independent verification.

SIGNAL 6 OF 6

ADM is the only named food-ingredient supplier publicly positioning GLP-1 formulation capability — the near-total silence from food-focused co-manufacturers indicates dedicated manufacturing investment has not yet begun

MEDIUM Short-term (3-12 months) • Infrastructure & Supply Chain Signals • Review

One major ingredient supplier (ADM) has posted GLP-1 formulation support capability, while the large capital commitments found in the research are concentrated entirely in pharmaceutical peptide manufacturing — indicating that food and supplement contract manufacturers have not yet made the investment bets that durable order volumes would normally trigger.

REASONING

This watch asks whether GLP-1 demand is generating durable manufacturing orders and investment. ADM's capability page is the only food/supplement supply-side signal found across all searches as of the date of this retrieval, though the page date could not be independently confirmed. CordenPharma's pharmaceutical peptide capacity investment and Novo Nordisk's multi-billion dollar facility buildout are large and verified, but they concern pharmaceutical peptide manufacturing — a different production system entirely. The gap between strong consumer-side demand data (signals 1-3) and near-absent supply-side investment announcements is itself analytically informative: it suggests manufacturers are watching demand evidence accumulate before committing capital. Confidence is held at Medium because the finding is one positive event (ADM positioning) interpreted against a backdrop of what the searches did not find; the absence of other announcements is scoped to this retrieval, not asserted as an absolute.

PATTERN

ADM published a GLP-1 user support products page stating its global team can provide 'science-backed ingredients and formulation know-how' for GLP-1-focused products across food, beverage, and dietary-supplement applications; the page date could not be independently confirmed from the available sources. CordenPharma announced a pharmaceutical peptide capacity investment program, including a third large-scale manufacturing facility at its Boulder, Colorado site — but this concerns pharmaceutical peptide manufacturing, not protein foods or supplements. Novo Nordisk is building a 9-billion-dollar active-pharmaceutical-ingredient facility in Kalundborg, Denmark and has invested 4.1 billion dollars in a U.S. fill-and-finish facility — again pharmaceutical, not food or supplement capacity. No second food or supplement contract manufacturer announcing dedicated GLP-1 production lines, capacity investment, or named brand partnerships was found in the current findings, though this reflects the scope of sources reviewed rather than an absolute absence.

IMPLICATION

A contract manufacturer that moves now to build and publicize GLP-1-specific formulation capability — particularly across the protein bar, protein powder, and frozen-meal formats that consumer data support — would occupy a relatively uncrowded supplier position. The window before capital commitments become widespread is still open, but the consumer-demand data in signals 1-3 suggest it will not stay open

indefinitely. ADM's positioning also signals that ingredient supply for protein, fiber, collagen, and creatine-based formulations is available; the bottleneck appears to be on the finished-product co-manufacturing side.

RECOMMENDED ACTION

Publish a dedicated GLP-1 formulation capability statement — covering protein bar, protein powder, ready-to-drink, and frozen-entrée formats — and identify a shortlist of three to five brand or retailer targets to approach directly before a second major co-manufacturer makes a public announcement.

SOURCES & WHAT THEY SIGNAL

- [**Novo Nordisk aims for 10-fold increase in oral GLP-1 manufacturing capacity \(Pharmaceutical Manufacturing\)**](#) — Multi-billion dollar pharmaceutical API and fill-and-finish investment — further evidence that large capital commitments in GLP-1 manufacturing are concentrated in the drug supply chain rather than food or supplement co-manufacturing.
- [**ADM GLP-1 user support products — formulation capability page**](#) — The only named food/supplement ingredient supplier found publicly marketing GLP-1 formulation capability — positioning across food, beverage, and dietary-supplement applications; page date could not be independently confirmed.
- [**CordenPharma GLP-1 CDMO investment — Pharmaphorum**](#) — Pharmaceutical peptide capacity investment — contextualizes where GLP-1-related manufacturing capital is currently flowing (drug side, not food/supplement side).

PUT A WATCH ON YOUR QUESTION

A watch on your question runs every cycle.

These signals came from one cycle of a standing watch. Name a company, a market or a regulation, and the watch keeps running whether or not anyone opens the platform. Every signal arrives rated for confidence and horizon, with the dated events behind it and the sources that carry the weight.

See all the samples and tell us your question at ezassi.com/ezassi-signals-sample-library.

info@ezassi.com • ezassi.com